AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 151 min read$IDXG

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

Original reporting
SEC EDGAR 8-K
Published Oct 15, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 10:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$IDXG
Bullish
medium confidence
Mentioned
$IDXG
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IDXGBullishMed
01

Why it matters

The preliminary revenue guidance signals continued growth, which may attract short‑term buying interest ahead of the final earnings release.

02

Market read

Micro‑cap biotech earnings guidance; relevant for traders focused on biotech earnings momentum.

03

What to watch

Potential delays in assay roll‑outs or reimbursement issues could dampen revenue growth.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Interpace Biosciences (NASDAQ: IDXG) provides thyroid diagnostic tests and is emerging in personalized medicine.

Company-level read

Ticker impact

$IDXGBullishMedium confidence
Context

Interpace Biosciences announced preliminary Q3 2026 revenue of $10.1M‑$10.4M, up ~11%‑14% QoQ.

Expected impact

likely slight upward pressure as market prices in higher revenue expectations

Evidence & confidence

Revenue guidance exceeds prior quarter and shows growth; investors may bid the stock higher pending final results.

Market effects

Sector

Positive signal for the molecular diagnostics sector, may lift peers.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact; primarily a micro‑cap specific event.

Counterpoint

What could challenge this read

If final results fall short of the preliminary range, the stock could face a sharp correction.

Key entities

  • company
    Interpace Biosciences, Inc.

    Issuer of the preliminary Q3 2026 revenue guidance.

Read at source← All news

Related articles

AUG 12
$IDXGMed

Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%

SEC EDGAR 8-K6 min
OCT 15
$FHNMed

First Horizon Corporation Reports Third Quarter 2026 Results and Announces Strategic Balance Sheet Changes to Support Earnings and Growth

FIRST HORIZON CORP (FHN) filed an SEC Form 8-K — Results of Operations and Financial Condition. First Horizon Corporation Reports Third Quarter 2026 Results and Announces Strategic Balance Sheet Changes to Support Earnings and Growth MEMPHIS, TN (October 15, 2026) – First Horizon Corporation (NYSE: FHN or “First Horizon”) today reported financial results for the third quart

SEC EDGAR 8-K2 min
OCT 15
$FMCHighAI 8/10

FMC expects $625M-$675M in charges from price cuts and a U.S. pricing shift.

FMC Corporation (NYSE:FMC) revised its Q3 2026 expectations, anticipating revenue of $510M and adjusted EBITDA between -$125M and -$565M due to price cuts and U.S. pricing shifts, totaling $625M-$675M in charges. The company cited weaker demand and high inventory levels as reasons for the adjustments. FMC plans to modify its pricing model and accelerate product movement to support future demand. The company will provide more details during its Q3 earnings call on October 29, 2026.

stocktitan.net2 min
OCT 15
$PLUGMed

Plug Power Reports Continued Business Progress, Sets Dates for Third Quarter 2026 Earnings Call and Global Plug Symposium

PLUG POWER INC (PLUG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Plug Power Reports Continued Business Progress, Sets Dates for Third Quarter 2026 Earnings Call and Global Plug Symposium · Company remains on track with 2026 revenue growth guidance, supported by continued margin improvement and a record low net cash usage of approx

SEC EDGAR 8-K2 min